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Background: Standardised	 clinical	 outcome	measures	 are	urgently	needed	 for	 the	















Berlin	 Cohort	 was	 slightly	 higher	 (mean	 15.26)	 compared	 to	 the	 Athens	 Cohorts	
(mean	10.86	and	11.13).	The	administration	of	antibiotics	was	most	prevalent	in	the	
Berlin	Cohort,	with	41.2%	on	antibiotics	(predominantly	cefuroxime)	as	opposed	to	
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1  | INTRODUC TION
Acute	 respiratory	 viral	 infections	 and	 influenza-like	 illness	 (ILI)	
are	among	the	most	common	reasons	for	primary	care	visits	and	
hospitalizations	 in	 children.	 Traditionally,	 hospitalization	 and	 ad-
mission	 to	 intensive	care	units	have	been	considered	criteria	 for	
“severe	 disease,”	 but	 clinical	 management	 decisions	 may	 differ	
from	 site	 to	 site.	 The	 European	Respiratory	 Society	 emphasized	
that	clinical	outcomes,	 in	particular	mortality	and	hospitalization	
rates	due	to	respiratory	illness,	vary	significantly	across	Europe.1 
For	 example,	 mortality	 appears	 to	 be	 higher	 in	 Eastern	 Europe,	
for	 reasons	 yet	 unknown.1	 Improved	 understanding	 of	 regional	
differences	 will	 require	 validated,	 standardized	 disease	 severity	
measures.2	 Standardized	 severity	 measures	 will	 allow	 cross-co-
hort	comparison	and	a	precision	medicine	approach	to	managing	
individual	 influenza	 infections	 in	 different	 risk	 groups.3	 Quality	
improvement	 programmes	 focused	 on	 optimizing	 treatment	 and	
prevention	efforts	depending	on	a	patient's	 individual	status	will	





We	 present	 the	 first	 multicentre	 quality	 improvement	 pro-
gramme	 implementing	 a	 standardized	 clinical	 severity	 measure	
for	 ILI	 in	 routine	 care.	 QI	 efforts	 are	 designed	 to	 induce	 sys-
tem-level	 change.	 The	 participating	 departments	 agreed	 to	 in-
troduce	an	institution-wide	standard	operating	procedure,	which	
is	 implemented	 in	 specific	 case	 scenarios	 (in	 this	 case,	 ILI)	with	
regular	 analysis	 and	 evaluation.	 The	 PEDSIDEA	 operating	 pro-
cedure	 was	 introduced	 into	 routine	 care	 as	 a	 “standing	 order”	
for	 predefined	 standardized	 disease	 severity	 assessments	 and	
















uncomplicated	disease	 (DSU1-9)	plus	13	weighted	 items	 reflecting	
complicated	disease	 (DSC	1-13)	 resulting	 in	 overall	 scores	 ranging	
from	0-48.2,3,5	Data	formats	and	terminologies	are	fully	compliant	
with	Clinical	Data	 Interchange	Standards	Consortium	 (CDISC)	 and	
regulatory	requirements.3
For	 validation	 in	 a	 multicentre	 quality	 improvement	 (QI)	 pro-
gramme,	the	ViVI	Score	was	made	available	as	a	mobile	application	
for	 android	 systems,	 linked	 to	 a	 central	 database.	 The	ViVI	 Score	
App	 (https://score.vi-vi.org)	 was	 provided	 by	 the	 Vienna	 Vaccine	





(Charité:	 EA24/008/10;	 Attikon:	 483/05-11-2014,	 Aghia	 Sophia:	
27509/2-12-2014).	 Informed	 consent	 procedures	were	waived	 for	
the	purpose	of	 enhanced	diagnostics	 and	quality	 of	 care.	At	 each	
site,	 monitoring	 throughout	 two	 consecutive	 influenza	 seasons	
(January-May	of	the	same	year	from	2014	to	2016)	was	required.
The	 severity	 assessments	were	 performed	 by	 independent	QI	
staff	in	patients	with	influenza-like	illness	(ILI),	at	the	time	of	initial	
presentation	 to	 the	emergency	room	 (ER)/hospital,	 that	 is	prior	 to	
any	 treatment	 decisions.2	 Assessments	 included	 the	 ViVI	Disease	
Severity	 Score,	 the	 ViVI	 Risk	 Factor	 Score	 (consisting	 of	 16	 un-
weighted	 items3)	 and	 three	 simple	 yes/no	 questions	 regarding	
planned	treatment	with	antibiotics	and/or	antivirals	and	the	patient's	
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2.2 | Virology
RT-PCR	 for	 influenza	A/B	viruses	was	performed	at	 the	Hellenic	
Pasteur	Institute,	Attikon	Hospital	and	the	Robert	Koch	Institute:	







using	 the	 QIAcube	 technology	 for	 automated	 extraction.	 All	




analysed	 at	 the	 Hellenic	 Pasteur	 Institute10	 using	 NucliSENS®	
easyMAG®	 platforms	 (bioMérieux	 Hellas)	 and	 an	 in-house	 mul-
tiplex	 real-time	 RT-PCR.	 The	 PCR	 protocol	 is	 validated	 accord-
ing	to	ISO	15189	requirements	and	deposited	with	the	European	
Influenza	 Surveillance	 Network.11	 Virological	 laboratories	 were	


















TA B L E  1  Patient	demographic	characteristics,	risk	factors	and	influenza	status	(n	=	1615)
Patient characteristic or risk factor 
(RF) Berlin (n = 1030) Aghia Sophia (n = 285) Attikon (n = 300)
PEDSIDEA 
(n = 1615)
Age	in	years	(mean;	range) 1.6	(0-5.9) 1.7	(0-5.7) 2.1	(0.04-5.8) 1.7	(0-5.9)
Gender	(males) 562	(54.6%) 151	(53.0%) 165	(55.0%) 878	(54.4%)
RF1:	Infant	under	2	y 717	(69.6%) 147	(51.6%) 151	(50.3%) 147	(51.6%)
RF2:	Pulmonary	condition 68	(6.6%) 7	(2.5%) 12	(4.0%) 87	(5.4%)
RF3:	Cardiac	condition 106	(10.3%) 0	(0.0%) 0	(0.0%) 106	(6.6%)
RF4:	Diabetes 3	(0.3%) 0	(0.0%) 0	(0.0%) 3	(0.2%)
RF5:	Obesity 1	(0.1%) 0	(0.0%) 1	(0.3%) 2	(0.1%)
RF6:	Other	metabolic	disease 23	(2.2%) 1	(0.4%) 1	(0.3%) 25	(1.6%)
RF7:	Chronic	renal	disease 24	(2.3%) 2	(0.7%) 0	(0.0%) 26	(1.6%)
RF8:	Chronic	hepatic	disease 10	(1.0%) 1	(0.4%) 0	(0.0%) 11	(0.7%)
RF9:	Neurologic	condition 57	(5.5%) 9	(3.2%) 8	(2.7%) 74	(4.6%)
RF10:	Haemoglobinopathies 11	(1.1%) 1	(0.4%) 1	(0.3%) 13	(0.8%)
RF11:	Congenital	
immunosuppression
2	(0.2%) 1	(0.4%) 0	(0.0%) 3	(0.2%)
RF12:	Acquired	immunosuppression 27	(2.6%) 0	(0.0%) 3	(1.0%) 30	(1.9%)
RF13:	Aspirin	therapy 18	(1.8%) 1	(0.4%) 0	(0.0%) 19	(1.2%)
RF14:	Pregnancy 0	(0.0%) 0	(0.0%) 0	(0.0%) 0	(0.0%)
RF15:	Elderly 0	(0.0%) 0	(0.0%) 0	(0.0%) 0	(0.0%)
RF16:	Prematurity 65	(6.3%) 12	(4.2%) 20	(6.7%) 97	(6.0%)
Total	ViVI	Risk	Factor	Score	(mean;	
range)
1.01 (0‐4) 0.60 (0‐3) 0.59 (0 −3) 0.86 (0‐4)
Confirmed	influenza	infection 114 (11.1%) 138 (48.4%) 99 (33.0%) 351 (21.7%)
Influenza	A 99	(9.6%) 119	(41.8%) 90	(30.0%) 308	(19.1%)
Influenza	B 15	(1.5%) 19	(6.7%) 9	(3.0%) 43	(2.7%)
Abbreviation(s):	ViVI,	Vienna	Vaccine	Safety	initiative.
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one	 in	Berlin)	were	 included	 in	 the	QI	 programme	 and	 analysis.	
The	success	rate	(completion	of	the	scoring	without	disruption	to	
the	 ED	workflow)	 was	 100%.	 The	mean	 age	 was	 1.7	 years	 (SD	
1.5;	range	0-5.9),	and	the	median	age	(IQR)	was	1.3	(0.5-2.7)	years	
for	 the	 overall	 PEDSIDEA	 cohort,	 and	 there	were	 54.4%	males.	
The	mean	RF-Score	was	0.86	 (SD	0.74,	 range	0-4)	given	a	maxi-
mum	possible	 RF-Score	 of	 16,	while	 the	median	RF-Score	 (IQR)	
was	1	 (0-1).	The	demographic	characteristics	and	distribution	of	
risk	 factors	 for	 the	overall	 cohort	and	by	study	site	are	summa-
rised	 in	Table	1,	while	the	distribution	of	RF-Scores	 is	plotted	 in	
Figure	1A,B.
3.2 | ViVI Disease Severity Score
The	mean	ViVI	Score	was	13.72	(SD	5.81;	range	0-35)	given	a	pos-




3.3 | Prescribing practices across PEDSIDEA sites
Oseltamivir	was	the	preferred	antiviral	across	all	three	sites	(Table	2).	
The	most	commonly	used	antibiotic	class	across	the	three	sites	was	
cephalosporins	 (cefotaxime,	 cefuroxime,	 ceftriaxone	 and	 cefprozil)	
followed	by	penicillins	 (amoxicillin,	ampicillin,	penicillin	and	amoxi-
cillin	 +	 clavulanate).	 In	 a	 few	 cases,	 antibiotic	 combinations	 were	
prescribed	 which	 included	 vancomycin,	 erythromycin,	 azithro-
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3.4 | Association between ViVI Risk Factor 
Score and treatment decisions in the ER, as well as 
reported antibiotic/antiviral pre‐exposures
No	significant	differences	in	mean	total	risk	factor	scores	(RF-Score)	





No	 significant	 difference	was	 observed	 in	 the	mean	 total	 RF-
Score	among	those	who	had	reported	any	previous	prescription	of	
antibiotics	 during	 the	 same	 disease	 episode	 (0.06	 [95%	 CI:	 −0.05	
to	 0.18];	 P	 =	 0.2857)	 or	 antivirals	 (0.14	 [95%	 CI:	 −0.06	 to	 0.35];	
P	=	0.1570).
3.5 | Correlation of ViVI Disease Severity Score 
with treatment decisions
ViVI	Disease	Severity	Scores	at	the	time	of	presentation	were	not	




sociated	with	 planned	 antibiotic	 treatment	 (mean	 ViVI	 Score	 in	
patients	where	antibiotics	were	planned	was	lower	at	11.47	[95%	
CI:	 10.69-12.24]	 as	 compared	 to	 that	 in	 patients	 where	 antibi-

















Scores	 in	 those	 who	 had	 received	 past	 antibiotic	 prescriptions	
(14.54;	 95%	 CI:	 13.64-15.43)	 as	 compared	 to	 those	 who	 had	 not	
(13.62;	95%	CI:	13.32-13.92);	P	=	0.0501.
3.6 | Correlation of ViVI Disease Severity Score 
with influenza infection







had	 not	 received	 a	 seasonal	 influenza	 vaccination	 (−0.10;	 95%	CI:	
−2.50	to	2.31);	P	=	0.9354.	 It	 should	be	noted,	however,	 that	only	
5/351	 (1.4%)	 influenza	 positive	 cases	 had	 received	 seasonal	 influ-
enza	vaccination	and	22/1255	(1.8%)	patients	without	influenza	had	
received	seasonal	influenza	vaccination.
3.7 | Correlation of ViVI Disease Severity Score 
with the ViVI Risk Factor Score
There	 was	 a	 significant	 but	 weakly	 positive	 correlation	 between	
the	RF-Score	and	the	ViVI	Score	 (Pearson's	correlation	coefficient	
0.2404; P	<	0.001).
TA B L E  2  ViVI	Disease	Severity	Score	criteria	and	treatment	decisions	(n	=	1615)
ViVI Score item/Prescribing practice Berlin (n = 1030)
Aghia Sophia 
(n = 285) Attikon (n = 300)
Overall PEDSIDEA 
(n = 1615)
DSU	1:	Fever 868	(84.3%) 253	(88.8%) 239	(79.7%) 1360	(84.2%)
DSU	2:	Cough 214	(71.3%) 244	(85.6%) 255	(85.0%) 1333	(82.5%)
DSU	3:	Pharyngitis 459	(44.6%) 178	(62.5%) 214	(71.3%) 851	(52.7%)
DSU	4:	Coryza/Rhinitis 799	(77.6%) 207	(72.6%) 268	(89.3%) 207	(72.6%)
DSU	5:	Headache 34	(3.3%) 13	(4.6%) 20	(6.7%) 67	(4.2%)
DSU	6:	Myalgia 13	(1.3%) 12	(4.2%) 12	(4.0%) 37	(2.3%)
DSU	7:	Malaise 263	(25.5%) 57	(20.0%) 199	(66.3%) 519	(32.1%)
DSU	8:	Diarrhoea 52	(17.3%) 42	(14.7%) 52	(17.3%) 285	(17.7%)
DSU	9:	Vomiting 330	(32.0%) 50	(17.5%) 55	(18.3%) 435	(26.9%)
DSC	1:	High	and	prolonged	fever 97	(9.4%) 33	(11.6%) 22	(7.3%) 152	(9.4%)
DSC	2:	Dyspnoea 499	(48.5%) 84	(29.5%) 75	(25.0%) 658	(40.7%)
DSC	3:	Hypoxia 304	(29.5%) 16	(5.6%) 38	(12.7%) 358	(22.2%)
DSC	4:	Haemoptysis 17	(1.7%) 3	(1.1%) 0	(0.0%) 20	(1.2%)
DSC	5:	Altered	or	loss	of	consciousness 30	(2.9%) 12	(4.2%) 31	(10.3%) 73	(4.5%)
DSC	6:	Seizure 108	(10.5%) 1	(0.4%) 0	(0.0%) 109	(6.8%)
DSC	7:	Dehydration 110	(10.7%) 6	(2.1%) 11	(3.7%) 127	(7.9%)
DSC	8:	Exacerbation	of	chronic	disease 4	(0.4%) 0	(0.0%) 9	(3.0%) 13	(0.8%)
DSC	9:	Septic	shock	or	multiorgan	
failure
3	(0.3%) 5	(1.8%) 0	(0.0%) 8	(0.5%)
DSC	10:	Need	for	hospitalisation 784	(76.1%) 156	(54.7%) 150	(50.0%) 1090	(67.5%)
DSC	11:	Lower	respiratory	tract	
infection/super-infection
881	(85.5%) 242	(84.9%) 235	(78.3%) 1358	(84.1%)
DSC	12:	Upper	respiratory	tract	infec-
tion/	super-infection
467	(45.3%) 117	(41.1%) 96	(32.0%) 680	(42.1%)
DSC	13:	Need	for	ICU	admission 321	(31.2%) 5	(1.8%) 8	(2.7%) 334	(20.7%)
Total	VIVI	SCORE	(mean;	range) 15.26 (0‐33) 10.86 (1‐35) 11.13 (0 −26) 13.72 (0‐35)
Antivirals	planned 2	(1.1%) 28	(9.8%) 53	(17.7%) 83	(10.9%)
Antivirals	prescribed 1	(0.5%) 6	(2.1%) 45	(15.0%) 52	(6.8%)
Antibiotics	planned 58	(31.7%) 64	(22.5%) 72	(24.0%) 214	(28.2%)
Antibiotics	prescribed 84	(41.2%) 21	(7.4%) 66	(22.0%) 171	(21.7%)
Abbreviation(s):	ViVI,	Vienna	Vaccine	Safety	initiative.
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3.8 | Risk‐adjusted ViVI Score: a new score based 
on disease severity and patient risk factors to predict 
patient outcomes and need for treatment
The	mean	Risk-adjusted	ViVI	Score	was	8.29	(SD	4.56;	range	0-32),	
while	 the	median	 (IQR)	was	7.5	 (5-10).	Figure	3A,B	shows	the	dis-
tribution	of	the	Risk-adjusted	ViVI	Score	for	the	overall	PEDSIDEA	
cohort	and	by	study	site.





ViVI	 Scores	 for	 patients	 who	 received	 antibiotics	 as	 compared	 to	
those	who	did	not	receive	antibiotics	(mean	Risk-adjusted	ViVI	Score	
of	9.21	[95%	CI:	8.39-10.02]	vs	8.18	[95%	CI:	7.95-8.41];	P	=	0.0051).
3.9 | Distribution of Risk‐adjusted ViVI Score by 
age and by viral aetiology
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Uniform	 outcome	 measures	 will	 facilitate	 the	 comparison	 of	
medical	 interventions	 in	 multicentre	 clinical	 trials	 and	 post-mar-
keting	 surveillance.	 Regulatory	 authorities	 in	 Europe	 and	 North	
America	have	called	for	standardized	clinical	outcome	measures	to	
facilitate	 the	 systematic	 evaluation	 of	 antiviral	 drugs.1,12-14	WHO	
priorities,	 at	 the	 same	 time,	 indicate	 that	 next-generation	 influ-





and	observational	 studies	of	 influenza	 and	other	 respiratory	viral	
infections.3
The	 ViVI	 Score	may	 be	 used	 to	 promote	 antibiotic	 steward-
ship.2	Severity	scoring	 in	conjunction	with	 reviews	of	 immuniza-
tion	records	and	targeted	bacterial	cultures	significantly	reduces	
the	 inappropriate	use	of	antibiotics	and	thus	cost.2	Standardized	
severity	 assessments	 in	 high-risk	 patients,	 combined	 with	 rapid	
diagnostics,	 could	 help	 to	 facilitate	 early	 treatment	 at	 the	 time	






tion”	 for	 their	 assumed	 risk	 factor	 profile,	 doctors	may	 feel	 the	
urge	to	use	antibiotics,	even	though	they	would	be	ineffective	in	
respiratory	viral	infections.












tiveness	will	 be	 studied	 in	 settings	where	 influenza	 vaccination	 is	
universally	recommended	in	children,	unlike	in	Germany	and	Greece,	
where	 no	 such	 recommendation	 has	 been	 issued	 and	where	 pae-
diatric	 vaccination	 rates	 are	 low.	 (see	www.keelp	no.gr	 for	Greece	
and	 https	://bit.ly/2C0FFUd	 for	 Germany).	 For	 further	 optimisa-
tion,	PEDSIDEA	samples	should	be	handled	by	one	central	 labora-
tory	or	using	one	diagnostic	method.	The	current	study	focused	on	
influenza.	The	 role	of	other	 viral	 and	bacterial	 pathogens	was	not	
assessed.	 It	was	suggested	that	co-infections	have	little	 impact,	or	
elicit	 less	 severe	 disease	 compared	 to	monoinfections.21	 Previous	
analyses	using	the	ViVI	Score	were	inconclusive	2,3 and require fur-
ther	investigation	in	multicentre	settings.
This	paper	aims	to	present	a	simple,	standardized	way	of	mea-





plore	 the	 relationship	 between	 severity	 and	 prescribing	 practices,	
cost,	and	other	outcome	measures	of	interest.






poorly	while	 eliciting	 considerable	 disease	 severity.23	Current	 sur-
veillance	systems	are	focused	on	numbers	and	mortality24	but	may	
be	 missing	 severe	 non-lethal	 disease.	 Our	 current	 knowledge	 is	
limited	with	respect	to	possible	mechanisms	underlying	severe	out-
comes	with	 influenza	 infection.25,26	 Standardized	 scoring	 systems	
will	be	key	to	the	identification	of	virus	and	host	factors	related	to	
severe	outcomes.27,28	Validated	biomarkers	predicting	severity	will	
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assist	future	physicians	in	tailoring	therapies	to	their	patients’	indi-
vidual	needs.










The	 Risk-adjusted	 ViVI	 Score	 allows	 the	 consistent	 measurement	
of	 disease	 severity	 in	 urgent	 care	 and	 multicentre	 settings.	 The	




implications	 for	 influenza	 surveillance	 and	 the	 critical	 evaluation	
of	 antibiotic	 and	 antiviral	 use,	 as	 well	 as	 vaccine	 effectiveness.29 
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